Endopyelotomy: Minimally Invasive Surgery for UPJ Obstruction — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endopyelotomy is a minimally invasive endoscopic surgical procedure designed to relieve ureteropelvic junction (UPJ) obstruction — a narrowing or blockage at the point where the renal pelvis (the funnel-shaped collecting system of the kidney) connects to the ureter (the tube that carries urine to the bladder). Untreated UPJ obstruction impairs urine drainage from the kidney, causing progressive hydronephrosis (kidney swelling), recurrent urinary tract infections, flank pain, and, if severe and prolonged, irreversible loss of renal function.

Unlike open pyeloplasty — which requires a flank incision and formal surgical reconstruction of the UPJ — endopyelotomy achieves relief of obstruction by making a precisely controlled full-thickness incision through the narrowed segment using an endoscope (a thin, flexible or rigid camera) advanced through the urinary tract. The incision divides the fibrous scar or abnormal tissue causing the narrowing, allowing the UPJ to heal in a wider configuration over a temporarily placed ureteral stent.

Endopyelotomy was first described by Wickham and Kellett in 1983 (percutaneous antegrade approach) and refined by Inglis and Tolley in 1990 (retrograde ureteroscopic approach). The procedure has since become a well-validated, widely performed option for selected patients with primary and recurrent UPJ obstruction, offering the advantages of minimal incisions, short hospital stay, rapid recovery, and preservation of the kidney's functional tissue.

The critical distinction between endopyelotomy and pyeloplasty is that endopyelotomy achieves success by incising the obstruction, while pyeloplasty achieves success by reconstructing it. This distinction has important implications for patient selection and long-term outcomes.

Endopyelotomy is specifically indicated for ureteropelvic junction obstruction and selected related conditions of the upper urinary tract.

• Primary UPJ Obstruction: The most common indication. Caused by an intrinsic narrowing of the UPJ — often due to an aperistaltic (non-contracting) ureteral segment, fibrous scar, or high ureteral insertion into the renal pelvis. Presents with flank pain (particularly after fluid intake), recurrent UTI, or incidental finding of hydronephrosis on imaging.
• Crossing Vessel-Related UPJ Obstruction: In approximately 30–40% of cases, an accessory lower pole renal artery crosses the UPJ and contributes to obstruction. Endopyelotomy is less effective in this group (success rates approximately 40–50%) compared to laparoscopic or robotic pyeloplasty, which can simultaneously transpose the crossing vessel.
• Recurrent UPJ Obstruction After Failed Pyeloplasty: Endopyelotomy is an effective second-line procedure for recurrent obstruction after open or laparoscopic pyeloplasty, with success rates of 75–85% in experienced centres.
• UPJ Obstruction with Concomitant Renal Calculi: The percutaneous (antegrade) approach allows simultaneous stone removal and endopyelotomy through the same nephrostomy access track — a significant advantage over retrograde ureteroscopic techniques.
• Ureterovesical Junction Obstruction: A related endoscopic incision technique (endoureterotomy) can be applied to obstructions at the ureter-bladder junction using similar principles.

Before endopyelotomy, renal function must be assessed with a diuretic nuclear renogram (MAG3 or DTPA scan) and cross-sectional imaging (CT urogram) to confirm: (1) obstruction is functionally significant, (2) the affected kidney retains sufficient differential function (typically greater than 25%) to justify intervention, and (3) no crossing vessel is the primary cause of obstruction.

Patient selection is critical to maximising endopyelotomy success rates. The urologist considers multiple anatomical, functional, and clinical factors.

Ideal candidates for endopyelotomy include:

• Patients with intrinsic UPJ obstruction without a crossing vessel on imaging (CT angiography or MR angiography)
• UPJ segment length less than 2 cm — longer strictures have significantly lower success rates
• Moderate to severe hydronephrosis (SFU grade 3–4) with preserved differential renal function ≥25%
• Recurrent UPJ obstruction after previous pyeloplasty (where redo open surgery carries higher complication risk)
• Adult patients with UPJ obstruction and concurrent renal pelvis calculi suitable for combined percutaneous treatment
• Patients who prefer a minimally invasive approach and are willing to accept slightly lower long-term success rates compared to pyeloplasty

Relative contraindications include:

• Crossing lower pole renal artery demonstrated on CT angiography (laparoscopic or robotic pyeloplasty preferred)
• Long UPJ stricture exceeding 2 cm
• Poorly functioning kidney with differential function below 20% (nephrectomy may be preferable)
• Active urinary tract infection at the time of planned procedure (requires antibiotic treatment to sterility before proceeding)
• Uncorrected coagulopathy (particularly relevant for percutaneous approach with renal puncture)
• Horseshoe kidney or ectopic kidney anatomy (increased technical complexity; laparoscopic approach may be preferred)

Three main endoscopic approaches to endopyelotomy are practiced, each with distinct advantages and clinical applications. The urologist selects the approach based on UPJ anatomy, patient factors, and institutional expertise.

• Retrograde Ureteroscopic Endopyelotomy: A flexible or semi-rigid ureteroscope is advanced through the urethra, bladder, and ureter to the UPJ under fluoroscopic guidance. A cold knife, hot-wire balloon (Acucise), or holmium:YAG laser fibre delivers a controlled lateral incision through the full thickness of the obstructed segment. A ureteral stent (typically 6F endopyelotomy stent with a tapered 14F upper segment) is then placed to maintain the incised opening during healing. No external incisions are required; this is a completely internal approach. Suitable for primary intrinsic UPJ obstruction without concomitant stones.
• Percutaneous Antegrade Endopyelotomy (Percutaneous Nephrostomy Approach): Under ultrasound and fluoroscopic guidance, a nephrostomy track is established through the flank directly into the renal collecting system. A nephroscope or ureteroscope is advanced through this track to the UPJ, and the incision is made under direct vision. Advantages include a larger working channel allowing stone removal, superior visualisation of the incision, and ability to use cold knife for precise cutting. Requires a 12–24 hour nephrostomy tube drainage after the procedure.
• Acucise Endopyelotomy (Hot-Wire Balloon): A retrograde technique using a balloon-cutting wire device that simultaneously dilates and electrosurgically incises the UPJ. Technically simpler and faster, but with slightly lower success rates and reduced visualisation compared to direct-vision endoscopy.
• Robotic-Assisted Endopyelotomy: An emerging hybrid approach combining robotic intracorporeal suturing capability with endoscopic visualisation; still investigational at most centres.

After incision by any approach, a double-J ureteral stent is placed across the incised UPJ and left for 4–6 weeks to maintain patency during the healing and remodelling phase.

Compared to open or laparoscopic pyeloplasty, endopyelotomy offers several practical advantages that make it an appealing first-line option for appropriately selected patients.

• Minimally Invasive: The retrograde approach requires no skin incisions at all. The percutaneous approach requires only a 5–8 mm flank puncture — far less than the 10–15 cm incision required for open pyeloplasty or the multiple 5–12 mm ports of laparoscopic surgery.
• Short Hospital Stay: Most patients are discharged 1–2 days after endopyelotomy. Open pyeloplasty typically requires 3–5 days of hospitalisation; laparoscopic pyeloplasty 2–3 days.
• Rapid Return to Activities: Patients typically return to desk work within 1–2 weeks and full physical activity within 3–4 weeks. Open surgery requires 4–6 weeks convalescence.
• Lower Operative Risk: The absence of major flank incision eliminates wound complications, reduces blood loss (typically under 50 mL for retrograde approach), and reduces the risk of adjacent organ injury compared to open surgery.
• Effective for Recurrent Cases: Endopyelotomy is particularly well suited to recurrent UPJ obstruction after pyeloplasty, where redo open surgery would encounter significant scarring and technical difficulty.
• Simultaneous Stone Treatment: The percutaneous approach allows treatment of coexisting renal pelvis calculi during the same anaesthetic session — a unique advantage over all other approaches.
• Cost-Effective: In most healthcare systems, endopyelotomy carries lower facility, anaesthesia, and recovery costs than laparoscopic pyeloplasty, making it an economically attractive option where success rates are comparable.

Endopyelotomy is generally safe, but carries specific risks related to its endoscopic and, for percutaneous cases, nephrostomy-related nature.

Intraoperative complications:

• Vascular Injury: The most feared complication, occurring in approximately 1–3% of cases. The lateral incision direction for endopyelotomy is specifically chosen to avoid the posterolateral renal pelvis blood supply, but inadvertent injury to a crossing vessel can cause significant haemorrhage requiring angiographic embolisation or rarely open surgery. Pre-operative CT angiography to map crossing vessels reduces this risk.
• Ureteral Perforation or Avulsion: Rare but serious; most common with excessive dilation or forceful instrumentation in a narrow ureter.

Early postoperative complications:

• Urinary Tract Infection / Urosepsis: Occurs in 3–8% of patients. Pre-operative urine culture and targeted antibiotic prophylaxis are mandatory to reduce risk. Patients with persistent bacteriuria require prolonged antibiotic treatment before elective endopyelotomy.
• Urine Leak: Extravasation around the nephrostomy track or UPJ incision site; usually resolves spontaneously with adequate ureteral stenting and nephrostomy drainage.
• Stent-Related Symptoms: The indwelling double-J stent causes bladder irritability, urinary frequency, urgency, and haematuria (blood in urine) in 30–60% of patients. These symptoms resolve completely after stent removal at 4–6 weeks.

Long-term issues:

• Treatment Failure / Re-stenosis: The primary limitation of endopyelotomy. Success rates of 80–90% for primary intrinsic UPJ obstruction, but 40–50% for crossing-vessel related obstruction. Failed cases require pyeloplasty. Follow-up imaging at 3 and 12 months is essential to detect early recurrence.

Recovery after endopyelotomy is significantly faster than after open pyeloplasty. Understanding the post-procedure timeline helps patients plan appropriately and recognise warning signs early.

Immediately after procedure: Patients typically remain in hospital for 1–2 days for monitoring, intravenous antibiotics, and (for percutaneous cases) nephrostomy tube management. The ureteral stent is left in position; patients are discharged with oral antibiotics and analgesics for stent-related discomfort.

With the stent in place (weeks 1–6): Stent-related symptoms — urgency, frequency, mild haematuria, and bladder spasms — are expected and managed with alpha-blockers (tamsulosin) and anticholinergics (solifenacin). Patients should maintain high fluid intake (2–3 litres daily) to flush the urinary system. Light activities are permitted from week 1; strenuous exercise, heavy lifting, and contact sports are deferred until after stent removal.

Stent removal: The double-J stent is removed cystoscopically under local or short general anaesthesia at 4–6 weeks. This is a brief day-case procedure. Symptoms resolve rapidly after removal.

Post-stent removal assessment:

• Diuretic renal scan (MAG3 nuclear renogram) at 3 months to assess drainage and confirm relief of obstruction
• Repeat scan at 12 months if the 3-month result shows improvement but not complete resolution
• CT urogram if recurrent symptoms develop — to confirm or exclude re-stenosis

Long-term outlook: Patients with confirmed resolution of obstruction on nuclear imaging require no further intervention. They are advised to report promptly any return of flank pain, fever, urinary tract infection, or declining urine output — symptoms that may indicate late re-stenosis occurring months to years after the initial procedure.

Endopyelotomy costs vary significantly by country, institution, surgical approach, and whether it is performed as a standalone procedure or combined with stone treatment.

• United States: Retrograde ureteroscopic endopyelotomy costs $8,000–$15,000 all-inclusive (surgeon, anaesthesia, facility, stent, follow-up). Percutaneous antegrade endopyelotomy: $12,000–$20,000 due to the more complex setup, fluoroscopy, and nephrostomy equipment. Most US health insurance plans cover endopyelotomy for medically indicated UPJ obstruction with appropriate prior authorisation.
• United Kingdom (NHS): Covered for eligible patients without direct cost. Private hospitals charge £4,000–£8,000 per procedure including the post-operative stent removal.
• India: Retrograde endopyelotomy at a leading tertiary urology centre costs ₹80,000–₹2,00,000 ($950–$2,400). Percutaneous endopyelotomy costs ₹1,20,000–₹3,00,000 ($1,400–$3,600), representing 70–85% savings compared to the US. High-volume urology centres in Chennai, Pune, Hyderabad, and Delhi offer internationally comparable outcomes.
• Thailand: $2,500–$5,000 at JCI-accredited hospitals in Bangkok with experienced urologists and modern ureteroscopy equipment.
• Turkey: €1,500–€4,000, making it one of the most affordable high-quality options for European patients.

Additional costs to consider: Pre-operative CT urogram and diuretic renogram ($300–$800), post-operative stent removal cystoscopy ($500–$1,000 in the US; $50–$100 in India), follow-up nuclear renogram, and urology clinic consultations. Medical tourism packages at leading Indian or Thai centres often bundle pre-operative investigations, surgery, stent removal, and initial follow-up into a single quoted price.

For UPJ obstruction, several surgical alternatives offer different trade-offs between invasiveness, success rate, and suitability for specific anatomical situations.

• Laparoscopic Dismembered Pyeloplasty (Anderson-Hynes): The current gold-standard treatment for UPJ obstruction with success rates of 94–98%, superior to all endoscopic techniques. The obstructed UPJ segment is completely excised and surgically reconstructed through a laparoscopic (keyhole) approach under general anaesthesia. Requires 2–3 days hospitalisation and 3–4 weeks recovery. Preferred for crossing vessel-related obstruction, long strictures, and primary cases in young patients where the highest long-term success rate is desired.
• Robotic-Assisted Pyeloplasty: Identical in concept to laparoscopic pyeloplasty but using the robotic surgical platform (da Vinci). Offers superior instrument articulation and 3D visualisation; particularly advantageous for obese patients or complex anatomical variants. Success rates equivalent to laparoscopic pyeloplasty. Available at major robotic surgery centres.
• Open Dismembered Pyeloplasty: The historical gold-standard with success rates above 95%, now largely replaced by laparoscopic and robotic approaches. Still used for complex renal anomalies (horseshoe kidney, ectopic kidney), young children where laparoscopic instruments may be too large, and when robotic or laparoscopic expertise is unavailable.
• Balloon Dilation of UPJ: Endoscopic dilation of the UPJ using a high-pressure balloon catheter without incision. Success rates significantly lower than endopyelotomy (40–60%) with high re-stenosis rates; rarely used as primary treatment in contemporary practice.
• Nephrectomy: Removal of the affected kidney is considered only when differential renal function is below 15–20% and the kidney is contributing minimally to total renal function. The combination of a non-functional kidney and recurrent infections may make nephrectomy the most pragmatic option in selected cases.

The choice between endopyelotomy and pyeloplasty should be individualised through shared decision-making between urologist and patient, weighing the higher success rate of pyeloplasty against the less invasive recovery of endopyelotomy in appropriately selected cases.